Quest Partners LLC Janux Therapeutics, Inc. Transaction History
Quest Partners LLC
- $920 Billion
- Q1 2025
A detailed history of Quest Partners LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 258 shares of JANX stock, worth $6,452. This represents 0.0% of its overall portfolio holdings.
Number of Shares
258
Previous 118
118.64%
Holding current value
$6,452
Previous $6.32 Million
10.26%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding JANX
# of Institutions
193Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$280 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$115 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$91.4 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$83.3 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$58.6 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.04B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...